Extracellular Vesicles as Drug Delivery Vehicles for Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1707

Special Issue Editors


E-Mail Website
Guest Editor
1 Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
2 Department of Surgery, Immunology Program, Cancer Program and Nanomedicine Translational Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
3 Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore
Interests: extracellular vesicles; cancer immunology; cell biology

E-Mail Website
Guest Editor
Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
Interests: extracellular vesicles; drug delivery; cancer immunotherapy; metastasis; microRNAs

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs) are lipid bilayer particles that function as carriers of intercellular communication under both physiological and pathological conditions. Not surprisingly, EVs have gained popularity as efficient vehicles, delivering therapeutic cargoes for cancer therapy. Nevertheless, efforts toward the standardization of methods of purification and production, drug loading and encapsulation, and surface functionalization for improved circulation kinetics and enhanced target specificity have yet to achieve the therapeutic potential of EVs for clinical use. Currently, EV microencapsulation with nanoporous biomaterials represents a great challenge in the field of controlled drug delivery. While the overwhelming majority of EV-based therapies in clinical trials consist of naïve EVs, contemporary progress in EV engineering is contributing to the development of more sophisticated drug delivery systems.

In this Special Issue, we invite the submission of review or original articles on all aspects related to EVs, including therapeutic applications of EVs for cancers, the loading of EVs with therapeutic cargoes, new approaches in targeted drug delivery, and regulatory considerations with regard to scale-up production, purity, safety, stability, and biocompatibility.

Dr. Thi Nguyet Minh Le
Dr. Boya Peng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery system
  • targeted delivery
  • microencapsulation
  • circulation kinetics
  • anticancer therapy
  • manufacturing process
  • clinical translation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

35 pages, 1416 KiB  
Review
Extracellular Vesicles as Drug Delivery System for Cancer Therapy
by Jin Wang, Bohang Yin, Jiabing Lian and Xia Wang
Pharmaceutics 2024, 16(8), 1029; https://doi.org/10.3390/pharmaceutics16081029 - 1 Aug 2024
Viewed by 1107
Abstract
In recent decades, the pursuit of drug delivery systems has led to the development of numerous synthetic options aimed at enhancing drug efficacy while minimizing side effects. However, the practical application of these systems is often hindered by challenges such as inefficiency, cytotoxicity, [...] Read more.
In recent decades, the pursuit of drug delivery systems has led to the development of numerous synthetic options aimed at enhancing drug efficacy while minimizing side effects. However, the practical application of these systems is often hindered by challenges such as inefficiency, cytotoxicity, and immunogenicity. Extracellular vesicles, natural carriers for drugs, emerge as promising alternatives with distinct advantages over synthetic carriers. Notably, EVs exhibit biocompatibility, low immunogenicity, and inherent tissue-targeting capabilities, thus opening new avenues for drug delivery strategies. This review provides an overview of EVs, including their biogenesis and absorption mechanisms. Additionally, we explore the current research efforts focusing on harnessing their potential as drug carriers, encompassing aspects such as purification techniques, drug loading, and bioengineering for targeted delivery. Finally, we discuss the existing challenges and future prospects of EVs as therapeutic agents in clinical settings. This comprehensive analysis aims to shed light on the potential of EVs as versatile and effective tools for drug delivery, particularly in the realm of cancer therapy. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Drug Delivery Vehicles for Cancer Therapy)
Show Figures

Figure 1

Back to TopTop